The HTLV-I envelope glycoproteins: Structure and functions

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue SUPPL. 1, 1996, Pages

  Delamarre, Lélia ^a   Rosenberg, Arielle R ^a   Pique, Claudine ^a   Pham, Danièle ^a   Callebaut, Isabelle ^b   Dokhélar, Marie Christine ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PIERRE ET MARIE CURIE   (France)

Author keywords

Envelope; Glycoproteins; HTLV I

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN; MEMBRANE PROTEIN; VIRUS PROTEIN;

CELL SURFACE; CONFERENCE PAPER; GLYCOSYLATION; HUMAN T CELL LEUKEMIA VIRUS 1; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; RECEPTOR BINDING; VIRUS ENVELOPE; VIRUS PARTICLE;

HTLV; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LYMPHOTROPIC VIRUS TYPE I; HUMAN T-LYMPHOTROPIC VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0029759629     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199600001-00015     Document Type: Conference Paper

References (54)

1. Hunter E, Swanstrom R. Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol 1990;157:187-253.
2. Gallaher WR, Ball JM, Garry RF, Martin-Amedee AM, Montelaro RC. A general model for surface glycoproteins of HIV and retroviruses. AIDS Res Hum Retroviruses 1995;11: 191-202.
3. Gallaher WR, Ball JM, Garry RF, Griffin MC, Montelaro RC. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989; 5:431-40.
4. Delwart EL, Mosialos G, Gilmore T. Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses 1990;6:703-6.
5. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992;89:10,537-41.
6. Cianciolo GJ, Kipnis RJ, Snyderman R. Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV. Nature 1984;311:515.
7. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985; 230:453-5.
8. Pique C, Pham D, Tursz T, Dokhélar MC. The cytoplasmic domain of the HTLV-I envelope can modulate the envelope functions in a cell type dependent manner. J Virol 1993;67: 557-61.
9. Pique C, Pham D, Tursz T, Dokhélar MC. Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation. J Virol 1992;66:906-13.
10. Pique C, Tursz T, Dokhélar MC. Mutations introduced along the HTLV-I envelope gene result in a non-functional protein: a basis for envelope conservation? EMBO J 1990;9: 4243-8.
11. Delamarre L, Pique C, Pham D, Tursz T, Dokhélar MC. Identification of functional regions in the HTLV-I SU glycoprotein. J Virol 1994;68:3544-9.
12. Paine E, Gu R, Ratner L. Structure and expression of the human T-cell leukemia virus type I envelope protein. Virology 1994;199:331-8.
13. Wild C, Dubay JW, Greenwell T, et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type I gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994;91:12,676-80.
14. Chen SS, Lee C, Lee W, McIntosh K, Lee T. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane protein. J Virol 1993;67:3615-9.
15. Bernstein HB, Tucker SP, Kar SR, et al. Oligomerization of the hydrophobic heptad repeat of gp41. J Virol 1995;69: 2745-50.
16. Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 1981;289:366-73.
17. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 1994;371:37-43.
18. Helenius A. Alphavirus and flavivirus glycoproteins: structures and functions. Cell 1995;81:651-3.
19. Harbury PB, Zhang T, Kim PS, Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 1993;262:1401-7.
20. Battini J, Heard JM, Danos O. Receptor choice determinants in the envelope glycoproteins of amphotropic, xeno-tropic, and polytropic murine leukemia viruses. J Virol 1992; 66:1468-75.
21. Kayman SC, Kopelman R, Projan S, Kinney DM, Pinter A. Mutational analysis of N-linked glycosylation sites of Friend murine leukemia virus envelope protein. J Virol 1991;65: 5323-32.
22. Denesvre C, Sonigo P, Corbin A, Ellerbrok H, Sitbon M. Influence of transmembrane domains on the fusogenic abilities of human and murine leukemia retrovirus envelopes. J Virol 1995;69:4149-57.
23. Carrington CV, Weiss RA, Schulz TF. A truncated HTLV-I envelope protein, lacking the hydrophobic membrane anchor domain, is associated with cellular membranes and virions. Virology 1994;202:61-9.
24. Landau NR, Page KA, Littman DR. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol 1991;65:162-9.
25. Miyamoto K, Tomita N, Ishii A, et al. Transformation of ATLA-negative leukocytes by blood components from anti-ATLA-positive donors in vitro. Int J Cancer 1984;33:721-5.
26. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984;46:245-53.
27. Popovic M, Sarin PS, Robert-Guroff M, et al. Isolation and transmission of human retrovirus (human T cell leukemia virus). Science 1983;219:856-9.
28. Nagy K, Clapham P, Cheingsong-Popov R, Weiss RA. Human T-cell leukemia virus type I: induction of syncytia and inhibition by patients' sera. Int J Cancer 1983;32:321-8.
29. Pique C, Saal F, Périés J, Pham D, Tursz T, Dokhélar MC. Functional comparison between HTLV-I envelopes originating from TSP/HAM or ATL cell lines. J Acquir Immune Defic Syndr 1994;7:319-24.
30. Hoshino H, Shimoyama M, Miwa M, Sugimura T. Detection of lymphocytes producing a human retrovirus associated with adult T-cell leukemia by syncytia induction assay. Proc Natl Acad Sci USA 1983;80:7337-41.
31. Fan N, Gavalchin J, Paul B, Wells KH, Lane MJ, Poiesz BJ. Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I. J Clin Microbiol 1992;30:905-10.
32. Hoffman PM, Dhib-Jalbut S, Mikovits JA, et al. Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures. Proc Natl Acad Sci USA 1992;89:11,784-8.
33. Koralnik IJ, Lemp JFJ, Gallo RC. In vitro infection of human macrophages by human T-cell leukemia/lymphotropic virus type I (HTLV-I). AIDS Res Hum Retroviruses 1992; 8:1845-9.
34. Sommerfelt MA, Williams BP, Clapham PR, Solomon E, Goodfellow PN, Weiss RA. Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science 1988;242:1557-9.
35. Fukudome K, Furuse M, Imai T, et al. Identification of membrane antigen C33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type I (HTLV-1)-induced syncytia formation: altered glycosylation of C33 antigen in HTLV-1-positive T cells. J Virol 1992;66:1394-401.
36. Gavalchin J, Fan N, Lane MJ, Papsidero L, Poiesz BJ. Identification of a putative cellular receptor for HTLV-I by a monoclonal antibody, Mab 34-23. Virology 1993;194:1-9.
37. Agadjanyan MG, Ugen KE, Wang B, Williams WV, Weiner DB. Identification of an 80-kilodalton membrane glycoprotein important for human T-cell leukemia virus type I and type II syncytium formation and infection. J Virol 1994;68: 485-93.
38. Baba E, Nakamura M, Tanaka Y, et al. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. J Immunol 1993;151:1013-24.
39. Kuroki M, Nakamura M, Itoyama Y, et al. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type I. J Immunol 1992;149:940-8.
40. Tanaka Y, Zeng L, Shiraki H, Shida H, Tozawa H. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol 1991;147:354-60.
41. Tanaka Y, Tanaka R, Terada E, et al. Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. J Virol 1994;68:6323-31.
42. Palker TJ, Riggs ER, Spragion DE, et al. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol 1992;66:5879-89.
43. Desgranges C, Souche S, Vernant JC, Smadja D, Vahlne A, Horal P. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera. AIDS Res Hum Retroviruses 1994;10:163-73.
44. Hoshino H, Nakamura T, Tanaka Y, Miyoshi I, Yanagihara R. Functional conservation of the neutralizing domains on the external envelope glycoprotein of cosmopolitan and Melanesian strains of human T cell leukemia/lymphoma virus type I. J Infect Dis 1993;168:1368-73.
45. Benson J, Tschachler E, Gessain A, et al. Cross-neutralizing antibodies against cosmopolitan and Melanesian strains of human T cell leukemia/lymphotropic virus type I in sera from inhabitants of Africa and the Solomon Islands. AIDS Res Hum Retroviruses 1994;10:91-6.
46. Gazzolo L, Due Dodon M. Direct activation of resting T lymphocytes by human T-lymphotropic virus type I. Nature 1987;326:714-7.
47. Kimata JT, Palker TJ, Ratner L. The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway. J Virol 1993; 67:3134-41.
48. Palker TJ, Tanner ME, Scearce RM, Streilein RD, Clark ME, Haynes BF. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. J Immunol 1989;142: 971-8.
49. Horal P, Hall WW, Svennerholm B, et al. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia virus type I and type II using synthetic peptides. Proc Natl Acad Sci USA 1991;88: 5754-8.
50. Chen YM, Lee T, Samuel KP, et al. Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people. J Virol 1989;63:4952-7.
51. Kuroda N, Washitani Y, Shiraki H, et al. Detection of antibodies to human T-lymphotrophic virus type I by using synthetic peptides. Int J Cancer 1990;45:865-8.
52. +, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM//TSP: recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. J Immunol 1991;146:1155-62.
53. Baba E, Nakamura M, Ohkuma K, et al. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. J Immunol 1995;154:399-412.
54. De Thé G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1995;9:381-6.